Sandbox GGC7: Difference between revisions
No edit summary |
No edit summary |
||
Line 10: | Line 10: | ||
[[Image:Signs-and-symptoms-of-hunter-syndrome.jpg]] | [[Image:Signs-and-symptoms-of-hunter-syndrome.jpg]] | ||
== Structural highlights == | == Structural highlights == | ||
<scene name='75/752270/Ide_mutations/2'>Scene 1: | <scene name='75/752270/Ide_mutations/2'>Scene 1: Mutation locations</scene> | ||
<scene name='75/752270/Ide_atp_binding-active_sites/1'>Scene 2: ATP binding active sites</scene> | <scene name='75/752270/Ide_atp_binding-active_sites/1'>Scene 2: ATP binding active sites</scene> | ||
<scene name='75/752270/Ide_n_and_c_terminals/1'>Scene 3: N and C terminals</scene> | |||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> |
Revision as of 09:25, 28 April 2021
Iduronate 2-sulfataseIduronate 2-sulfatase
Iduronate 2-sulfatase (I2S), also referred to as Alpha-L-iduronate sulfate sulfatase or Idursulfase, is a lysosomal enzyme involved in the degradation pathway of dermatan sulfate and heparan sulfate.[1] FunctionIduronate 2-sulfatase is located in the lysosome.[1] It is involved in the lysosomal degradation pathway of dermatan sulfate and heparan sulfate.[1] I2S hydrolyzes the 2-sulfate groups of the L-iduronate 2-sulfate units of dermatan sulfate, heparan sulfate and heparin.[1] Dermatan sulfate and heparan sulfate are complex glycosaminoglycans, which are essentially large sugar molecules.[2] They play important roles in cell adhesion, growth, proliferation and repair, and their degradation and recycling in the lysosome are essential for cellular maintenance.[2] RelevanceMutations in Iduronate 2-sulfatase can lead to Mucopolsaccharidosis 2 (MPS2), more commonly known as Hunter syndrome.[1] MPS2 is an X-linked lysosomal storage disease.[1] It is characterized by the intracellular accumulation of the glycosaminoglycans heparan sulfate and dermatan sulfate, which are then excreted in urine.[1] It is rare to find adults with Hunter syndrome as the average life expectancy for those with MPS2 is 15 years of age.[1] Most children diagnosed with MPS2 have somatic abnormalities including skeletal deformities, hepatosplenomegaly, and progressive cardiopulmonary deterioration.[1] Neurological damage is also prevalent beginning with what seems to be a developmental delay and hyperactivity, but progresses to mental retardation and dementia.[1] Structural highlights
|
|